KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Long-Term Deferred Tax (2018 - 2025)

Takeda Pharmaceutical (TAK) has 6 years of Long-Term Deferred Tax data on record, last reported at $2.4 billion in Q1 2025.

  • For Q1 2025, Long-Term Deferred Tax fell 8.57% year-over-year to $2.4 billion; the TTM value through Mar 2025 reached $2.4 billion, down 8.57%, while the annual FY2025 figure was $2.4 billion, 10.88% down from the prior year.
  • Long-Term Deferred Tax reached $2.4 billion in Q1 2025 per TAK's latest filing, down from $2.7 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $3.3 billion in Q1 2021 and bottomed at $2.4 billion in Q1 2025.
  • Average Long-Term Deferred Tax over 5 years is $2.9 billion, with a median of $2.8 billion recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: dropped 11.3% in 2023, then dropped 3.95% in 2024.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $3.3 billion in 2021, then fell by 6.66% to $3.1 billion in 2022, then decreased by 11.3% to $2.8 billion in 2023, then decreased by 3.95% to $2.7 billion in 2024, then decreased by 8.57% to $2.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $2.4 billion in Q1 2025, $2.7 billion in Q1 2024, and $2.8 billion in Q1 2023.